Simcere Pharmaceutical Group Limited (FRA:S2P)

Germany · Delayed Price · Currency is EUR

1.260

+0.030 (2.44%)

Last updated: Aug 26, 2026, 8:08 AM CET

-14.86% (1Y)

Market Cap	3.26B -14.5%
Revenue (ttm)	1.12B +22.8%
Net Income	202.52M +81.4%
EPS	0.08 +73.0%
Shares Out	n/a
PE Ratio	16.08
Forward PE	14.31
Dividend	0.02 (1.76%)
Ex-Dividend Date	Jun 17, 2026

Volume	n/a
Open	1.260
Previous Close	1.230
Day's Range	1.260 - 1.260
52-Week Range	1.000 - 1.600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini... [Read more]

Industry Pharmaceutical Preparations

Founded 1995

Employees 7,038

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol S2P

Financial Performance

In 2025, FRA:S2P's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY Financial Statements